Albumin–hydroxyethyl starch interface

The Albumin–hydroxyethyl starch interface refers to the physicochemical interaction between human serum albumin, the most abundant protein in human plasma, and hydroxyethyl starch (HES), a synthetic polysaccharide used as a volume expander (Qu et al., 2024). This interface is not a biological therapeutic target in the traditional sense, such as a receptor or enzyme, but is a subject of study in pharmacology and nanomedicine (Freichels et al., 2013). Research focuses on how HES molecules bind to albumin, potentially altering its secondary structure and affecting its capacity to transport endogenous and exogenous ligands (Qu et al., 2024). In the development of drug delivery systems, this interface is utilized to create HES-albumin nanoparticles, which aim to enhance the stability and targeted delivery of chemotherapeutic agents (Freichels et al., 2013). Clinically, the interaction is relevant during fluid resuscitation, where the choice between albumin and HES can impact patient outcomes related to oncotic pressure, coagulation, and renal function (Myburgh et al., 2013; NIH, 2013).

Other names

HES-albumin interactionHydroxyethyl starch-albumin complexHES-albumin nanoparticle interfaceAlbumin-HES binding site

Not a therapeutic target; refers to the physical interaction between a plasma protein and a synthetic colloid used in volume expansion and drug delivery.